학술논문
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Document Type
Article
Author
Kristeleit, R.; Lisyanskaya, A.; Fedenko, A.; Dvorkin, M.; de Melo, A.C.; Shparyk, Y.; Rakhmatullina, I.; Bondarenko, I.; Colombo, N.; Svintsitskiy, V.; Biela, L.; Nechaeva, M.; Lorusso, D.; Scambia, G.; Cibula, D.; Póka, R.; Oaknin, A.; Safra, T.; Mackowiak-Matejczyk, B.; Ma, L.; Thomas, D.; Lin, K.K.; McLachlan, K.; Goble, S.; Oza, A.M.
Source
In: The Lancet Oncology . (The Lancet Oncology, April 2022, 23(4):465-478)
Subject
Language
English
ISSN
14745488
14702045
14702045